Abstract: In some embodiments, a data set is selected based on one or more applications experiencing events. A first analysis of the data set is received that classifies the data set into a first set of failures using an analysis engine configured with first classification logic that performs the classifying. A portion of the data set is selected to re-run based on the first set of failures. A second analysis of the portion of the data set is received that classifies the portion of the data set into a second set of failures using the analysis engine that is configured with second classification logic. A correlation of one or more first failures that shift to one or more second failures is determined. An annotation describing the shift in the one or more first failures to the one or more second failures is then output.

Abstract: In some embodiments, a data set is selected based on one or more applications experiencing events. A first analysis of the data set is received that classifies the data set into a first set of failures using an analysis engine configured with first classification logic that performs the classifying. A portion of the data set is selected to re-run based on the first set of failures. A second analysis of the portion of the data set is received that classifies the portion of the data set into a second set of failures using the analysis engine that is configured with second classification logic. A correlation of one or more first failures that shift to one or more second failures is determined. An annotation describing the shift in the one or more first failures to the one or more second failures is then output.

Abstract: A system, optical assembly, and optical communication system are disclosed. The optical assembly is disclosed as including an optoelectronic component having a predetermined shape and an optical module that permits light emitted by the optoelectronic component or travelling to the optoelectronic component to pass therethough. The optical module is further disclosed as including a first surface and an opposing second surface, the first surface of the optical module including a first mating feature to receive the optoelectronic component, and the second surface of the optical module including a receptacle to receive and align an optical fiber with the optoelectronic component.

Abstract: A system, optical assembly, and optical communication system are disclosed. The optical assembly is disclosed as including an optoelectronic component having a predetermined shape and an optical module that permits light emitted by the optoelectronic component or travelling to the optoelectronic component to pass therethough. The optical module is further disclosed as including a first surface and an opposing second surface, the first surface of the optical module including a first mating feature to receive the optoelectronic component, and the second surface of the optical module including a receptacle to receive and align an optical fiber with the optoelectronic component.

Abstract: Various VCSEL device packages and VCSEL array configurations are disclosed. In one example, a device contains two or more VCSELs, each VCSEL having a substantially triangular body. Such device packages allow for denser VCSEL array configurations than those provided by traditional VCSEL device packages. The denser VCSEL array configurations not only allow for more VCSELs to be batch manufactured per wafer but also allow for denser layouts on various mounting surfaces.

Abstract: The present invention relates to a method of producing rough strains of a bacterium, such as Mycobacterium obuense, said method comprising exposing said bacterium to a sulfone and/or sulfonamide (such as 4,4?-Diaminodiphenyl sulfone or an analogue thereof). A rough strain of Mycobacterium obuense producible by said method and uses thereof. In particular, uses of a rough strain of Mycobacterium obuense deposited under the Budapest Treaty at the NCTC with the accession number NCTC 13365.

Abstract: Use of whole cells of bacteria from the genera of aerobic organisms in the order of Actinomycetales in the manufacture of a medicament for the treatment or prevention of Type II diabetes and/or obesity and methods of treating or preventing Type II diabetes and/or obesity in a subject by administering an effective amount of a composition comprising a whole cell of a bacterium from a genera of aerobic organisms in the order of Actinomycetales to said subject. Preferably the bacteria is from one or more of the following genera for example: Gordonia, Rhodococcus, Tsukamurella, Nocardia, Dietzia and Mycobacterium.

Abstract: The present invention relates to a method of producing rough strains of a bacterium, such as Mycobacterium obuense, said method comprising exposing said bacterium to a sulfone and/or sulfonamide (such as 4,4?-Diaminodiphenyl sulfone or an analogue thereof). A rough strain of Mycobacterium obuense producible by said method and uses thereof. In particular, uses of a rough strain of Mycobacterium obuense deposited under the Budapest Treaty at the NCTC with the accession number NCTC 13365.

Abstract: The present invention relates to a method of producing rough strains of a bacterium, such as Mycobacterium obuense, said method comprising exposing said bacterium to a sulfone and/or sulfonamide (such as 4,4?-Diaminodiphenyl sulfone or an analogue thereof). A rough strain of Mycobacterium obuense producible by said method and uses thereof. In particular, uses of a rough strain of Mycobacterium obuense deposited under the Budapest Treaty at the NCTC with the accession number NCTC 13365.

Abstract: The present invention relates to a method of producing rough strains of a bacterium, such as Mycobacterium obuense, said method comprising exposing said bacterium to a sulfone and/or sulfonamide (such as 4,4?-Diaminodiphenyl sulfone or an analogue thereof). A rough strain of Mycobacterium obuense producible by said method and uses thereof. In particular, uses of a rough strain of Mycobacterium obuense deposited under the Budapest Treaty of NCTC with the accession number NCTC 13365.

Abstract: Use of a composition comprising a whole cell of a bacterium from a genus of aerobic organisms in the order of Actinomycetales in the manufacture of a medicament for modulating the immune response of a recipient wherein said composition is administered to a subject and said recipient is exposed to a bodily of said subject whilst said recipient is an infant. Preferably the medicament is used for the prevention and/or treatment of one or more of: an infection, an allergy, an autoimmune-based disease and a neoplasm in said recipient.

Abstract: An immune modulator composition and/or pharmaceutical composition comprising a whole cell of a bacterium from the genera Rhodococcus, Gordonia, Nocardia, Dietzia, Tsukamurella and Nocardioides, wherein said immune modulator composition in use modifies a cellular immune response.

Abstract: Use of whole cells of bacteria from the genera of aerobic organisms in the order of Actinomycetales in the manufacture of a medicament for the treatment or prevention of stress-induced pulmonary haemorrhage (SIPH), preferably exercise induced pulmonary haemorrhage (EIPH), and methods of treating or preventing SIPH, preferably EIPH, in a subject by administering an effective amount of a composition comprising a whole cell of a bacterium from a genera of aerobic organisms in the order of Actinomycetales to said subject. Preferably the aerobic organism is from one or more of the following genera for example: Tsukamurella, Rhodococcus, Gordonia, Nocardia, Dietzia and Mycobacterium.

Abstract: This invention relates to a method for treating or preventing (including immunising against) post-wearing multisystemic wasting syndrome (PMWS) and/or porcine dermatitis and nephropathy syndrome (PDNS) in a subject comprising administering an effective amount of a pharmaceutical composition or immune modulator composition comprising a whole cell of a bacterium from one or more of the genera Rhodococcus, Gordonia, Nocardia, Dietzia, Tsukamurella and Nocardioides, to said subject. In addition the method relates to the use of an immune modulator composition or a pharmaceutical composition comprising a whole cell of a bacterium from the genera Rhodococcus, Gordonia, Nocardia, Dietzia, Tsukamurella and Nocardioides, in the manufacture of a medicament for the treatment or prevention of post-wearing multisystemic wasting syndrome (PMWS) and/or porcine dermatitis and nephropathy syndrome (PDNS).

Abstract: Use of an immune modulator composition and/or pharmaceutical composition comprising a whole cell of a bacterium from the genera Rhodococcus, Gordonia, Nocardia, Dietzia, Tsukamurella and Nocardioides, for use in the manufacture of a medicament for the treatment of an autoimmune disease or autoimmune disorder, including certain vascular disorders.

Abstract: Use of an immune modulator composition and/or pharmaceutical composition comprising a whole cell of a bacterium from the genera Rhodococcus, Gordonia, Nocardia, Dietzia, Tsukamurella and Nocardioides, for use in the manufacture of a medicament for the treatment of an autoimmune disease or autoimmune disorder, including certain vascular disorders.

Abstract: An immune modulator composition and/or pharmaceutical composition comprising a whole cell of a bacterium from the genera Rhodococcus, Gordonia, Nocardia, Dietzia, Tsukamurella and Nocardioides, wherein said immune modulator composition in use modifies a cellular immune response.

Abstract: The invention relates to a method for treating or preventing (including immunising against) post-weaning multisystemic wasting syndrome (PMWS) and/or porcine dermatitis and nephropathy syndrome (PDNS) in a subject comprising administering an effective amount of a pharmaceutical composition or immune modulator composition comprising a whole cell of a bacterium from one or more of the genera Rhodococcus, Gordonia, Nocardia, Dietzia, Tsukamurella and Nocardioides, to said subject. In addition the method relates to the use of an immune modulator composition or a pharmaceutical composition comprising a whole cell of a bacterium from the genera Rhodococcus, Gordonia, Nocardia, Dietzia, Tsukamurella and Nocardioides, in the manufacture of a medicament for the treatment or prevention of post-weaning multisystemic wasting syndrome (PMWS) and/or porcine dermatitis and nephropathy syndrome (PDNS).